Suppr超能文献

放射治疗后血管生成和免疫调节的血液生物标志物变化及其与胸部恶性肿瘤预后的关系

Changes in Blood Biomarkers of Angiogenesis and Immune Modulation after Radiation Therapy and Their Association with Outcomes in Thoracic Malignancies.

作者信息

Gkika Eleni, Adebahr Sonja, Brenner Anton, Schimek-Jasch Tanja, Radicioni Gianluca, Exner Jan-Philipp, Rühle Alexander, Spohn Simon K B, Popp Ilinca, Zamboglou Constantinos, Sprave Tanja, Firat Elke, Niedermann Gabriele, Nicolay Nils Henrik, Nestle Ursula, Grosu Anca-Ligia, Duda Dan G

机构信息

University Medical Center Freiburg, Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.

German Cancer Consortium (DKTK), 79106 Freiburg, Germany.

出版信息

Cancers (Basel). 2021 Nov 16;13(22):5725. doi: 10.3390/cancers13225725.

Abstract

The effects of radiotherapy on systemic immunity remain to be fully characterized in a disease-specific manner. The aim of the study was to examine potential biomarkers of systemic immunomodulation when using radiotherapy for thoracic malignancies. Serial blood samples were collected from 56 patients with thoracic malignancies prior (RTbaseline), during (RTduring) and at the end of radiotherapy (RTend), as well as at the first (FU1) and second follow-up (FU2). The changes in serum levels of IL-10, IFN-γ, IL-12p70, IL-13, IL-1β, IL-4, IL-6, IL-8, TNF-α, bFGF, sFlt-1, PlGF, VEGF, VEGF-C, VEGF-D and HGF were measured by multiplexed array and tested for associations with clinical outcomes. We observed an increase in the levels of IL-10, IFN-γ, PlGF and VEGF-D and a decrease in those of IL-8, VEGF, VEGF-C and sFlt-1 during and at the end of radiotherapy. Furthermore, baseline concentration of TNF-α significantly correlated with OS. IL-6 level at RTend and FU1,2 correlated with OS (RTend: = 0.039, HR: 1.041, 95% CI: 1.002-1.082, FU1: = 0.001, HR: 1.139, 95% CI: 1.056-1.228, FU2: = 0.017, HR: 1.101 95% CI: 1.018-1.192), while IL-8 level correlated with OS at RTduring and RTend (RTduring: = 0.017, HR: 1.014, 95% CI: 1.002-1.026, RTend: = 0.004, HR: 1.007, 95% CI: 1.061-1.686). In conclusion, serum levels of TNF-α, IL-6 and IL-8 are potential biomarkers of response to radiotherapy. Given the recent implementation of immunotherapy in lung and esophageal cancer, these putative blood biomarkers should be further validated and evaluated in the combination or sequential therapy setting.

摘要

放疗对全身免疫的影响仍有待以疾病特异性方式进行全面表征。本研究的目的是在使用放疗治疗胸部恶性肿瘤时,检测全身免疫调节的潜在生物标志物。从56例胸部恶性肿瘤患者放疗前(放疗基线)、放疗期间(放疗中)、放疗结束时(放疗末)以及首次随访(FU1)和第二次随访(FU2)时采集系列血样。通过多重阵列检测血清中白细胞介素-10(IL-10)、干扰素-γ(IFN-γ)、白细胞介素-12p70(IL-12p70)、白细胞介素-13(IL-13)、白细胞介素-1β(IL-1β)、白细胞介素-4(IL-4)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)、碱性成纤维细胞生长因子(bFGF)、可溶性血管内皮生长因子受体-1(sFlt-1)、胎盘生长因子(PlGF)、血管内皮生长因子(VEGF)、血管内皮生长因子-C(VEGF-C)、血管内皮生长因子-D(VEGF-D)和肝细胞生长因子(HGF)水平的变化,并检测其与临床结局的相关性。我们观察到放疗期间及放疗结束时IL-10、IFN-γ、PlGF和VEGF-D水平升高,而IL-8、VEGF、VEGF-C和sFlt-1水平降低。此外,TNF-α的基线浓度与总生存期显著相关。放疗末及FU1、FU2时的IL-6水平与总生存期相关(放疗末:P = 0.039,风险比:HR = 1.041,95%置信区间:1.002 - 1.082;FU1:P = 0.001,HR = 1.139,95%置信区间:1.056 - 1.228;FU2:P = 0.017,HR = 1.101,95%置信区间:1.018 - 1.192),而IL-8水平在放疗中及放疗末与总生存期相关(放疗中:P = 0.017,HR = 1.014,95%置信区间:1.002 - 1.026;放疗末:P = 0.004,HR = 1.007,95%置信区间:1.061 - 1.686)。总之,TNF-α、IL-6和IL-8的血清水平是放疗反应的潜在生物标志物。鉴于近期免疫疗法在肺癌和食管癌治疗中的应用,这些假定的血液生物标志物应在联合或序贯治疗环境中进一步验证和评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d200/8616228/b91b6db3d527/cancers-13-05725-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验